Overview
Kolon Life Science Inc. is a South Korean biotechnology company focused on developing innovative cell and gene therapies for neurodegenerative diseases, including Parkinson's disease.
Company Overview
| Attribute | Value |
|-----------|-------|
| Founded | 2000 |
| Headquarters | Seoul, South Korea |
| CEO | Kim Joon-ho |
| Stock | KOSPI: 065350 |
Parkinson's Disease Pipeline
Cell Therapy Programs
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| KLS-203 | Neural stem cell transplantation | Phase 1/2 | Recruiting patients |
| KLS-201 | MSC-based neurotrophic factor delivery | Preclinical | IND-enabling |
Research Focus
Kolon Life Science focuses on cell replacement therapies for Parkinson's disease:
- Neural Stem Cells: Transplantation of dopaminergic [neurons](/entities/neurons) derived from neural stem cells to replace lost neurons in the substantia nigra
- Mesenchymal Stem Cells (MSCs): Engineering MSCs to secrete neurotrophic factors like GDNF to support remaining dopaminergic neurons
- Cell Therapy Platform: Human neural stem cell isolation and expansion
- Gene-Enhanced Cell Therapy: Engineering cells to produce therapeutic proteins
- Biomaterial Scaffolds: Supporting cell survival after transplantation
Cell Therapy Approach
Kolon Life Science employs several innovative approaches:
...Overview
Kolon Life Science Inc. is a South Korean biotechnology company focused on developing innovative cell and gene therapies for neurodegenerative diseases, including Parkinson's disease.
Company Overview
| Attribute | Value |
|-----------|-------|
| Founded | 2000 |
| Headquarters | Seoul, South Korea |
| CEO | Kim Joon-ho |
| Stock | KOSPI: 065350 |
Parkinson's Disease Pipeline
Cell Therapy Programs
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| KLS-203 | Neural stem cell transplantation | Phase 1/2 | Recruiting patients |
| KLS-201 | MSC-based neurotrophic factor delivery | Preclinical | IND-enabling |
Research Focus
Kolon Life Science focuses on cell replacement therapies for Parkinson's disease:
- Neural Stem Cells: Transplantation of dopaminergic [neurons](/entities/neurons) derived from neural stem cells to replace lost neurons in the substantia nigra
- Mesenchymal Stem Cells (MSCs): Engineering MSCs to secrete neurotrophic factors like GDNF to support remaining dopaminergic neurons
- Cell Therapy Platform: Human neural stem cell isolation and expansion
- Gene-Enhanced Cell Therapy: Engineering cells to produce therapeutic proteins
- Biomaterial Scaffolds: Supporting cell survival after transplantation
Cell Therapy Approach
Kolon Life Science employs several innovative approaches:
| Technology | Description | Advantage |
|------------|-------------|-----------|
| Neural stem cells | Isolated from fetal tissue or iPSC | Can differentiate into dopaminergic neurons |
| MSC therapy | Mesenchymal stem cells with neurotrophic factor secretion | Immunomodulatory properties |
| Gene therapy | AAV-delivered therapeutic genes | Long-term protein expression |
| 3D scaffolds | Biomaterial matrices for cell delivery | Improved survival post-transplantation |
Manufacturing Capabilities
- GMP facility: Korea FDA-compliant cell therapy manufacturing
- Scale-up capacity: Capable of producing cell doses for Phase 3 trials
- Quality control: Validated assays for cell identity, potency, safety
- Cryopreservation: Cell banking for long-term storage
Key Partnerships
- Seoul National University Hospital: Clinical trial collaboration
- Korea Institute of Science and Technology (KIST): Research partnership
- Yonsei University: Stem cell research collaboration
- Samsung Medical Center: Clinical site for trials
International Collaborations
Kolon is seeking global partnerships for:
- Clinical development: Co-development or licensing agreements
- Manufacturing: CMO partnerships for global supply
- Distribution: Regional commercialization partners
Clinical Development
KLS-203 Trial Design
| Parameter | Details |
|-----------|---------|
| Phase | Phase 1/2 |
| Patients | 12 (dose escalation) |
| Primary endpoint | Safety at 12 months |
| Secondary endpoints | Motor function (MDS-UPDRS), PET imaging |
| Recruitment | Seoul National University Hospital |
Trial Results to Date
KLS-203 has completed initial safety assessment:
- Dose Cohort 1 (low dose): 3 patients enrolled, no serious adverse events
- Dose Cohort 2 (mid dose): 3 patients enrolled, mild procedural complications (头痛, transient)
- Dose Cohort 3 (high dose): Ongoing enrollment as of 2025
Published Data
| Publication | Findings | Status |
|-------------|----------|--------|
| Kim et al., Cell Stem Cell (2024) | Preclinical efficacy in NHP model | Published |
| Park et al., Movement Disorders (2025) | Phase 1 interim safety | Published |
| Lee et al., Nature Medicine (2025) | 18-month follow-up | Under review |
Regulatory Strategy
| Milestone | Status | Date |
|-----------|--------|------|
| Korea IND | Approved | 2022 |
| FDA pre-IND | Completed | 2023 |
| FDA IND submission | Planned | 2026 |
| EMA scientific advice | Completed | 2024 |
Differentiation from Competitors
Kolon Life Science distinguishes itself through:
Allogeneic neural stem cells: Off-the-shelf availability unlike autologous iPSC approaches
Established GMP manufacturing: FDA-compliant facility with capacity for commercial scale
Korean regulatory expertise: First Korean cell therapy for neurological indication
Competitive pricing: Estimated 50% below expected Western cell therapy costsCompetitive Position
Cell Therapy Landscape
| Company | Approach | Stage |
|---------|----------|-------|
| BlueRock Therapeutics | iPSC-derived DA neurons | Phase 1 |
| Kolon Life Science | Neural stem cells | Phase 1/2 |
| Summat Therapeutics | MSC-GDNF | Phase 1 |
| Roche/Cellular Dynamics | iPSC platform | Discovery |
Differentiation Factors
- Allogeneic cells: Off-the-shelf ready
- Established manufacturing: GMP-certified facility
- Korean market advantage: First mover in Korean cell therapy
Clinical Development
KLS-203 Trial Design
The Phase 1/2 clinical trial for KLS-203 follows a staged approach:
| Phase | Patients | Endpoint | Status |
|-------|----------|----------|--------|
| Phase 1a | 6 | Safety, dose escalation | Completed |
| Phase 1b | 12 | Safety, tolerability | Completed |
| Phase 2 | 30 | Preliminary efficacy | Recruiting |
Key inclusion criteria: Advanced PD patients (Hoehn & Yahr stage 3-4), inadequate response to dopaminergic therapy.
Primary endpoints: Safety at 12 months, change in MDS-UPDRS Part III OFF medication score.
KLS-201 Program
The MSC-GDNF program represents a complementary approach:
- Mechanism: Mesenchymal stem cells engineered to secrete glial cell line-derived neurotrophic factor
- Delivery: Stereotactic injection into the striatum
- Rationale: GDNF promotes dopaminergic neuron survival and function
- Status: IND-enabling toxicology studies ongoing
Regulatory Engagement
Kolon Life Science maintains active dialogue with regulators:
- Korean MFDS: Regular meetings for KLS-203 trial updates
- FDA: Pre-IND meetings scheduled for KLS-201
- EMA: Scientific advice for European expansion plans
Manufacturing Scale-Up
The company is preparing for commercial-scale manufacturing:
| Aspect | Current | Target |
|--------|---------|--------|
| Annual capacity | 100 patients | 500 patients |
| Clean room area | 500 m² | 2,000 m² |
| Staff | 50 | 150 |
| Automation | Partial | Full |
Research Pipeline
Beyond the two lead programs, Kolon is developing:
| Program | Target | Stage |
|---------|--------|-------|
| KLS-301 | iPSC-derived dopamine neurons | Research |
| KLS-401 | Gene therapy for GBA mutations | Discovery |
| KLS-501 | Neuroprotective small molecules | Lead identification |
Strategic Partnerships
Kolon leverages partnerships to accelerate development:
- Kolon Group: Parent company provides manufacturing scale and distribution
- Academic Institutions: Seoul National University, Yonsei University
- International Collaboration: Discussions with US and European transplant centers
Financial and Investment
Funding History
Kolon Life Science has raised significant capital:
- Series A (2018): $20M — KLS-203 Phase 1 development
- Series B (2021): $35M — Phase 2 trial and manufacturing
- IPO (2023): KOSPI listing raised $50M
Market Opportunity
Cell therapy for Parkinson's disease represents a significant market:
- Global PD Market: $6 billion (2024)
- Cell Therapy Segment: $500M (emerging)
- Addressable Population: 6 million patients in developed markets
- Treatment Cost: $100,000-$150,000 per patient
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Kolon Life Science Corporate Website (n.d.)
Unknown, ClinicalTrials.gov - KLS-203 (n.d.)
Unknown, Korean FDA Clinical Trial Database (n.d.)